Active Share (vs S&P 500): 97.5%
· vs QQQ: 98.1%
— share of the book that differs from index weights (higher = more active)
· ranking
Est. Qtr Return (Q2 2026 → Q3 2026):
-11.2%
· vs SPY
-13.3%
· Prev Value $2.22B
— last quarter positions weighted by this quarter price moves
· ranking
Est. QTD Return (Q3 2026 → newest close):
-0.3%
· vs SPY
-2.5%
· Latest Value $1.54B
— latest reported positions valued at quarter-to-date price moves (still in progress)
· ranking
In its Q3 2026 13F filing, Integral Health Asset Management, LLC disclosed 94 equity positions with a combined reported value of $1.54B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 41.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were RVMD ($130.34M), INSM ($128.98M), CYTK ($72.50M). By sector, the heaviest allocations are Health Care 96.1%, Industrials 1.7%. Versus the prior quarter, allocation shifted toward Health Care (+3.1pp), Industrials (+0.7pp) and away from Consumer Staples (-3.7pp).
Versus the prior quarter, Integral Health Asset Management, LLC opened 35 new positions, trimmed 28 and fully exited 31, a turnover rate of 75.2% of positions. The portfolio's overlap with the prior quarter was 47% of names.
The largest new positions opened in Q3 2026 were AMGN ($31.61M), INCY ($19.42M), ONC ($18.30M).
Of the 31 positions fully exited versus the prior quarter, the largest were ALHC ($47.62M), ABT ($36.30M), UNH ($35.33M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
Latest Integral Health Asset Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Integral Health Asset Management, LLC, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 94 positions worth $1.54B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Regulatory AUM (Form ADV): $1.87B as of 2026-03-26
Client mix (by RAUM): pension and profit-sharing plans 100%
Manages 1 private funds, of which 1 hedge funds
Website: integralhlth.com
Portfolio Structure
94 positions · $1.54B reported value (Q3 2026)
Top 10 holdings = 41.9% of reported value
Largest position: RVMD (REVOLUTION MEDICINES INC) at 8.4%
Average position size: $16.41M
Sector Tilt
Health Care 96.1%
Industrials 1.7%
Consumer Staples 1.4%
(classified holdings cover 99% of value)
Quarterly Activity
Q3 2026: 35 new, 12 added, 28 reduced, 31 exited
19 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
AI Rebalance Analysis
1. Overall direction and market view: The fund is actively increasing exposure to high-growth biotech/healthcare names (RVMD, SRRK, CNC) and large-cap healthcare (MRK, AMGN), while reducing positions in smaller/mid-cap biotechs (AXSM, VERA, LFST), suggesting a tactical tilt toward larger, more established players with potential upside.
2. Key moves:
- Added: RVMD (shares +233.3%), MRK (+28.6%), SRRK (+67.3%), CNC (+150.0%).
- Reduced: AXSM (-16.7%), VERA (-14.3%), LFST (-13.3%).
- New: AMGN (initial position).
- Held: INSM, CYTK.
3. Portfolio structure: Active, concentrated (94 positions), heavily biased toward Health Care (100% of top 10). Moderate risk appetite—mix of high-growth biotech (RVMD, SRRK) and stable large-caps (MRK, AMGN).
4. Per-holding one-liner:
- RVMD: Biotech developing cancer therapies (unverified).
- INSM: Biotech focused on rare diseases (unverified).
- CYTK: Biotech targeting muscular/heart diseases (unverified).
- MRK: Large-cap pharmaceutical (Merck).
- SRRK: Biotech developing muscle-targeted therapies (unverified).
- CNC: Managed healthcare provider (Centene).
- AXSM: Biotech pain therapeutics (unverified).
- VERA: Biotech kidney/immunology drugs (unverified).
- AMGN: Large-cap biotech (Amgen).
- LFST: Mental healthcare provider (Lifestance).
5. Style summary: The fund tactically shifted toward larger, more established healthcare names while selectively boosting high-growth biotech positions, reducing exposure to smaller/mid-cap biotechs.
Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:31
Every 13F share count is marked to the quarter-end close, rebuilding the NAV this
portfolio would have earned had it done nothing all quarter. This is a historical
reconstruction from already-public filings and prices — not a model forecast, so
precision/recall do not apply.
2024-Q4 = 100. Solid = reconstructed NAV, dashed = SPY benchmark.
Prices are split-adjusted closes and exclude dividends, so dividend-heavy
portfolios would in reality sit slightly above this line.
This portfolio is broadly diversified (Top-10 = 40.4% of reported value), so a
Top-10 proxy cannot represent the whole fund — only the full-holdings reconstruction is shown.
Why there is no forecast NAV
Not published because:
Top-10 covers < 85% of reported value · Holdings-forecast backtest F1 < 0.80 · Top-10 quarterly turnover > 20%
Source: full 13F positions marked to quarter-end closes (computed 2026-11-02 01:13:11).
Share counts and prices are used as a ratio, so splits cancel out.
Holdings Prediction Model
Predicts next-quarter Top-10 holdings and weights from the fund's own historical
trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative
volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through
quarter T. Weights are shares of the modelled portfolio.
The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.
Latest-Quarter Accuracy (2026-Q3)
P 40%R 40%F1 40%(modelled on 2026-Q2; 4/10 hit)
Low-confidence forecast
This fund replaces about 48% of its Top-10 each quarter and
backtests at F1 54% (threshold 80%).
Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.
★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.
Barra Factor Attribution
The disclosed long US equity book from the 2026-Q3 13F is held at its
report-date weights and decomposed over 2026-09-30 ~ 2026-11-16.
The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional
factor returns and an EWMA factor covariance for risk. The “portfolio” is the
visible 13F book, not the fund's true NAV.
The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.
Portfolio return+1.28%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+18.30%vs benchmark
Barra annualised vol26.6%Model estimate
Realised vol27.4%Annualised in window
Weighted beta0.67Raw exposure
Factor / specific risk60% / 40%Share of variance
Top-10 concentration71.8%Of reported value
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.
1. Performance
Metric
Value
Note
Portfolio return (buy & hold)
+1.28%
Disclosed long book
QQQ synthetic benchmark
-17.01%
Liquidity-weighted constituents
Model universe, equal weight
-1.70%
Opportunity-cost reference
Excess return
+18.30%
Portfolio − benchmark
Arithmetic return sum
+1.75%
Difference vs compounded is the cross term
Weighted raw beta
0.67
Weighted holding betas
Realised volatility (annualised)
27.44%
Daily returns in window
Barra model volatility (annualised)
26.64%
Factor + specific
Factor share of variance
59.8%
Barra factors
Specific share of variance
40.2%
Stock residuals
Reported value
$778.0M
13F long US equity
2. Return attribution
The +1.75% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.
Factor group
Factors
Contribution
Share of |return|
Size & Liquidity
6
+2.12%
121.2%
Momentum & Growth
3
-4.60%
-263.1%
Volatility & Tail Risk
7
+4.84%
276.8%
Industry
12
+6.91%
395.1%
Specific
1
-7.52%
-429.9%
Factor
Type
Exposure
Factor return
Contribution
Share of |return|
Health Care
Industry
+0.94
+6.98%
+6.55%
374.5%
Kurtosis
Style
+0.82
+7.51%
+6.19%
353.8%
Residual Volatility
Style
+1.46
+3.29%
+4.80%
274.4%
Size
Style
-0.66
-1.95%
+1.29%
73.8%
Turnover
Style
-0.17
-4.80%
+0.81%
46.4%
Leverage (Downside Vol)
Style
-0.42
-1.71%
+0.73%
41.5%
Non-linear Size
Style
+0.55
+1.01%
+0.55%
31.6%
Short-term Reversal
Style
+0.53
+0.87%
+0.46%
26.5%
Consumer Staples
Industry
+0.03
+12.82%
+0.35%
20.2%
Mid Cap
Style
+0.13
-1.94%
-0.25%
-14.5%
Amihud Illiquidity
Style
+0.71
-0.45%
-0.31%
-18.0%
Growth
Style
-0.44
+1.75%
-0.76%
-43.6%
Beta
Style
-0.20
+4.44%
-0.87%
-49.6%
Historical Volatility
Style
+0.21
-14.00%
-2.89%
-165.4%
Skewness
Style
+0.71
-4.39%
-3.13%
-179.0%
Momentum
Style
+1.08
-4.00%
-4.30%
-246.0%
Specific
Specific
—
—
-7.52%
-429.9%
3. Risk attribution
Annualised volatility is 26.64%; factor risk explains 59.8% of variance and specific risk 40.2%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.
Factor
Type
Exposure
Share of variance
Vol contribution
Share of vol
Specific
Specific
—
40.2%
+10.70%
10.7%
Health Care
Industry
+0.94
33.6%
+8.96%
9.0%
Momentum
Style
+1.08
12.4%
+3.30%
3.3%
Residual Volatility
Style
+1.46
4.9%
+1.31%
1.3%
Kurtosis
Style
+0.82
3.5%
+0.93%
0.9%
Size
Style
-0.66
3.0%
+0.81%
0.8%
Leverage (Downside Vol)
Style
-0.42
1.8%
+0.48%
0.5%
Short-term Reversal
Style
+0.53
1.5%
+0.40%
0.4%
Amihud Illiquidity
Style
+0.71
1.3%
+0.35%
0.3%
Consumer Staples
Industry
+0.03
0.6%
+0.16%
0.2%
Industrials
Industry
+0.03
0.5%
+0.14%
0.1%
Historical Volatility
Style
+0.21
-0.2%
-0.07%
-0.1%
Skewness
Style
+0.71
-0.5%
-0.13%
-0.1%
Non-linear Size
Style
+0.55
-1.1%
-0.30%
-0.3%
Beta
Style
-0.20
-1.7%
-0.46%
-0.5%
4. Style exposures
Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.
Style factor
Portfolio
QQQ benchmark
Difference
Size
-0.66
+2.10
-2.76
Non-linear Size
+0.55
+1.68
-1.13
Mid Cap
+0.13
+0.13
+0.01
Beta
-0.20
+1.29
-1.49
Momentum
+1.08
+0.72
+0.36
Short-term Reversal
+0.53
-0.64
+1.17
Residual Volatility
+1.46
-0.40
+1.86
Historical Volatility
+0.21
+0.86
-0.65
Liquidity
+0.09
+0.11
-0.02
Amihud Illiquidity
+0.71
+1.16
-0.45
Turnover
-0.17
+0.21
-0.38
Growth
-0.44
+0.58
-1.02
Leverage (Downside Vol)
-0.42
+0.14
-0.57
Skewness
+0.71
+0.24
+0.47
Kurtosis
+0.82
+0.21
+0.61
Max Drawdown
-0.01
-0.08
+0.07
5. Industry allocation & Brinson
Sector
Portfolio
Benchmark
Portfolio ret
Benchmark ret
Allocation
Selection
Interaction
Total
Information Technology
0.0%
73.6%
+0.00%
-22.33%
+3.83%
+16.44%
-16.44%
+16.44%
Health Care
93.8%
1.7%
+1.23%
+8.29%
+23.40%
-0.12%
-6.50%
+1.01%
Communication Services
0.0%
2.6%
+0.00%
-17.64%
+0.01%
+0.46%
-0.46%
+0.46%
Consumer Staples
2.8%
0.8%
+3.38%
+15.26%
+0.62%
-0.10%
-0.23%
-0.03%
Utilities
0.0%
0.8%
+0.00%
+11.13%
-0.22%
-0.09%
+0.09%
-0.09%
Consumer Discretionary
0.0%
8.8%
+0.00%
+3.76%
-1.84%
-0.33%
+0.33%
-0.33%
Industrials
3.4%
11.1%
-7.09%
+4.36%
-1.65%
-1.27%
+0.88%
-0.73%
Total
+24.04%
+14.96%
-22.30%
+16.70%
6. Holdings & contribution
Symbol
Name
Sector
Weight
Return
Contribution
QoQ
RVMD
REVOLUTION MEDICINES INC
Health Care
16.75%
-18.70%
-3.13%
Add
INSM
INSMED INC
Health Care
16.58%
+7.66%
+1.27%
Hold
MRK
MERCK & CO INC
Health Care
8.40%
-0.58%
-0.05%
Add
SRRK
SCHOLAR ROCK HLDG CORP
Health Care
7.80%
-7.82%
-0.61%
Add
CNC
CENTENE CORP DEL
Health Care
5.99%
+20.36%
+1.22%
Add
AMGN
AMGEN INC
Health Care
4.06%
+9.68%
+0.39%
New
REGN
REGENERON PHARMACEUTICALS
Health Care
3.90%
+25.60%
+1.00%
Hold
TNGX
TANGO THERAPEUTICS INC
Health Care
2.89%
-3.13%
-0.09%
Hold
CVS
CVS HEALTH CORP
Consumer Staples
2.75%
+3.38%
+0.09%
Reduce
VRTX
VERTEX PHARMACEUTICALS INC
Health Care
2.69%
+2.86%
+0.08%
Hold
BBIO
BRIDGEBIO PHARMA INC
Health Care
2.54%
+17.57%
+0.45%
Add
ONC
BEONE MEDICINES LTD
Health Care
2.35%
+12.39%
+0.29%
New
ROIV
ROIVANT SCIENCES LTD
Health Care
2.35%
+5.58%
+0.13%
Hold
BDX
BECTON DICKINSON & CO
Health Care
2.30%
+20.93%
+0.48%
New
BSX
BOSTON SCIENTIFIC CORP
Health Care
2.24%
+0.09%
+0.00%
Reduce
MDT
MEDTRONIC PLC
Health Care
1.94%
+19.23%
+0.37%
Reduce
NVS
NOVARTIS AG
Health Care
1.83%
+12.37%
+0.23%
Reduce
MDGL
MADRIGAL PHARMACEUTICALS INC
Health Care
1.62%
-15.87%
-0.26%
Hold
BMY
BRISTOL-MYERS SQUIBB CO
Health Care
1.60%
+1.89%
+0.03%
New
LIVN
LIVANOVA PLC
Health Care
1.47%
+20.84%
+0.31%
Reduce
Contribution rank
Symbol
Sector
Weight
Return
Contribution
1
INSM
Health Care
16.58%
+7.66%
+1.27%
2
CNC
Health Care
5.99%
+20.36%
+1.22%
3
REGN
Health Care
3.90%
+25.60%
+1.00%
4
BDX
Health Care
2.30%
+20.93%
+0.48%
5
BBIO
Health Care
2.54%
+17.57%
+0.45%
6
AMGN
Health Care
4.06%
+9.68%
+0.39%
7
MDT
Health Care
1.94%
+19.23%
+0.37%
8
LIVN
Health Care
1.47%
+20.84%
+0.31%
9
MDGL
Health Care
1.62%
-15.87%
-0.26%
10
TXG
Industrials
0.81%
-39.14%
-0.32%
11
ALNY
Health Care
0.95%
-35.26%
-0.34%
12
SRRK
Health Care
7.80%
-7.82%
-0.61%
13
RVMD
Health Care
16.75%
-18.70%
-3.13%
7. Conclusions
Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned +1.28%, versus -17.01% for the QQQ synthetic benchmark — an excess of +18.30%.
Return attribution: the largest positive style/industry contributions came from Health Care +6.55%, Kurtosis +6.19%, Residual Volatility +4.80%; the largest drags came from Momentum -4.30%, Skewness -3.13%, Historical Volatility -2.89%. Specific (stock-level) return contributed -7.52%.
Risk attribution: Barra model volatility is 26.64% annualised; factor risk explains 60% of variance and specific risk 40%. The largest factor risk sources are Health Care 33.6%, Momentum 12.4%, Residual Volatility 4.9%.
Style tilt: size -0.66, momentum +1.08, volatility +0.21, liquidity +0.09; the weighted raw beta is 0.67. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
Industry: the largest overweight versus the benchmark is Health Care (+92.1 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +24.04%, selection +14.96% and interaction -22.30%.
Concentration: the top-10 positions are 71.8% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.
FAQ
What did Integral Health Asset Management, LLC buy in 2026-Q3?
In its 2026-Q3 13F filing, Integral Health Asset Management, LLC reported 94 equity positions worth $1.54B in aggregate; its largest disclosed positions were RVMD ($130.34M), INSM ($128.98M), CYTK ($72.50M).
How large is Integral Health Asset Management, LLC's portfolio?
Integral Health Asset Management, LLC reported $1.54B of long equity holdings across 94 positions as of 2026-Q3. Top-10 holdings account for 41.9% of reported value.
What is Integral Health Asset Management, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.
Embed this fund on your site
Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.
<iframe src="https://holdingshub.top/funds/integral-health-asset-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>